Treating leukemia: differentiation therapy for mIDH2 AML

被引：2
|
作者：
Sun, Xiao-Jian [1 ]
Chen, Sai-Juan [1 ]
Chen, Zhu [1 ]
机构：
[1] Shanghai Jiao Tong Univ, State Key Lab Med Genom, Natl Res Ctr Translat Med, Shanghai Inst Hematol,Ruijin Hosp,Sch Med, Shanghai 200025, Peoples R China
来源：
CELL RESEARCH | 2019年 / 29卷 / 06期
关键词：
ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; ENASIDENIB; PATHWAY;
D O I：
10.1038/s41422-019-0173-4
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
While the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) in the treatment of acute promyelocytic leukemia (APL) has been a remarkably successful example for differentiation therapy of cancer, the recently developed therapeutics of mutant IDH2 (mIDH2)-associated leukemia by specific mIDH2 inhibitors is launching another promising campaign. Interestingly, a recent study in Cell Research by Mugoni et al. demonstrated a sensitivity of the mIDH2 leukemia to the APL-like ATRA/ATO combination therapy, narrating a convergence of two tales.
引用
收藏
页码：427 / 428
页数：2
相关论文
共 50 条
  • [1] Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy
    Mugoni, Vera
    Panella, Riccardo
    Cheloni, Giulia
    Chen, Ming
    Pozdnyakova, Olga
    Stroopinsky, Dina
    Guarnerio, Jlenia
    Monteleone, Emanuele
    Lee, Jonathan David
    Mendez, Lourdes
    Menon, Archita Venugopal
    Aster, Jon Christopher
    Lane, Andrew A.
    Stones, Richard Maury
    Galinsky, Ilene
    Zamora, Jose Cervera
    Lo-Coco, Francesco
    Bhasin, Manoj Kumar
    Avigan, David
    Longo, Letizia
    Clohessy, John Gerard
    Pandolfi, Pier Paolo
    CELL RESEARCH, 2019, 29 (06) : 446 - 459
  • [2] An ATRActive future for differentiation therapy in AML
    Johnson, Daniel E.
    Redner, Robert L.
    BLOOD REVIEWS, 2015, 29 (04) : 263 - 268
  • [3] PRAMEing a Picture of Differentiation Therapy for AML?
    Redner, Robert L.
    CLINICAL CANCER RESEARCH, 2013, 19 (09) : 2277 - 2279
  • [4] Differentiation therapy of leukemia: 3 decades of development
    Nowak, Daniel
    Stewart, Daphne
    Koeffler, H. Phillip
    BLOOD, 2009, 113 (16) : 3655 - 3665
  • [5] VEGFC Antibody Therapy Drives Differentiation of AML
    Kampen, Kim R.
    Scherpen, Frank J. G.
    Mahmud, Hasan
    ter Elst, Arja
    Mulder, Andre B.
    Guryev, Victor
    Verhagen, Han J. M. P.
    De Keersmaecker, Kim
    Smit, Linda
    Kornblau, Steven M.
    de Bont, Eveline S. J. M.
    CANCER RESEARCH, 2018, 78 (20) : 5940 - 5948
  • [6] Differentiation therapy of myeloid leukemia: four decades of development
    Madan, Vikas
    Koeffler, H. Phillip
    HAEMATOLOGICA, 2021, 106 (01) : 26 - 38
  • [7] Differentiation therapy of acute myeloid leukemia: past, present and future
    Petrie, Kevin
    Zelent, Arthur
    Waxman, Samuel
    CURRENT OPINION IN HEMATOLOGY, 2009, 16 (02) : 84 - 91
  • [8] Acute myeloid leukemia maturation lineage influences residual disease and relapse following differentiation therapy
    Ngo, Steven
    Oxley, Ethan P.
    Ghisi, Margherita
    Garwood, Maximilian M.
    McKenzie, Mark D.
    Mitchell, Helen L.
    Kanellakis, Peter
    Susanto, Olivia
    Hickey, Michael J.
    Perkins, Andrew C.
    Kile, Benjamin T.
    Dickins, Ross A.
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [9] Kinase Inhibitors and Interferons as Other Myeloid Differentiation Inducers in Leukemia Therapy
    Takahashi, Shinichiro
    ACTA HAEMATOLOGICA, 2022, 145 (02) : 113 - 121
  • [10] Mebendazole for Differentiation Therapy of Acute Myeloid Leukemia Identified by a Lineage Maturation Index
    Li, Yulin
    Thomas, Daniel
    Deutzmann, Anja
    Majeti, Ravindra
    Felsher, Dean W.
    Dill, David L.
    SCIENTIFIC REPORTS, 2019, 9 (1)
12345